For example, in the model of humanized cord blood (CB)-HSC mice, nivolumab (anti-PD-1 antibody) inhibited the growth of MDA-MB-231 triple negative breast cancer and CRC172 colorectal cancer cells, stimulating an antitumor T-cell response by the increase in the number of granzyme B (GrB) or interferon (IFN)-γ CD8+ T-cells in the tumors [102]. Here, GZMB is linked to triple-negative breast carcinoma.